If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
In October 2013, Basilea received marketing authorisation in twelve European countries, including Germany, for the distribution of the broad-spectrum antibiotic Ceftobiprole for the treatment of bacterial lung infections; in the following two years, the drug was gradually approved in other European countries and non-EU countries. Ceftobiprole has been approved in 32 countries and has been marketed in 21 countries since the end of 2023. In 2020, Basilea sold the group headquarters in Basel to the pension fund of the Swiss bank UBS by way of a sale-leaseback and moved to its new headquarters in Allschwil in mid-2022. The gross proceeds from the sale amounted to around CHF 19 million before fees and transaction costs. In 2021, Basilea Pharmaceutica China Ltd. was sold to the US company PHT International. Basilea was previously active in oncological research, but withdrew from it at the beginning of 2022 and has since been focusing purely on anti-infectives. In 2023, Basilea acquired the rights to the antifungal drug Fosmanogepix from Pfizer. By the end of 2023, Isavuconazole was commercialised in more than 70 countries, including the United States, most EU countries, China and Japan. Isavuconazole's total global sales in the twelve-month period between October 2022 and September 2023 amounted to CHF 406 million. This corresponds to growth of 22 per cent compared to the previous year.
== Awards and recognition == Reith and her two collaborators were recognised on 28 March 1984 in an early day motion in the House of Commons, tabled by Michael Forsyth and other MPs. She was made a Commander of the Order of the British Empire (CBE) in the 2023 Birthday Honours, "for services to people with diabetes". She was given a Lifetime Achievement award at the 2024 Pride Of Britain Awards.
=== Nutrition === Raw blackcurrants are 82% water, 15% carbohydrates, 1% protein and 0.4% fat (table). Per 100 g serving providing 63 kilocalories, the raw fruit has high vitamin C content (218% of the Daily Value, DV) and moderate levels of iron and manganese (12% DV each). Other nutrients are present in negligible amounts (less than 10% DV, table). Blackcurrant seed oil is rich in vitamin E and unsaturated fatty acids, including alpha-linolenic acid and gamma-linolenic acid.
Cholesterol is the principal sterol of all animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Cholesterol is biosynthesized by all animal cells and is an essential structural and signaling component of animal cell membranes. In vertebrates, hepatic cells typically produce the greatest amounts of it. In the brain, astrocytes produce cholesterol and transport it to neurons. It is absent among prokaryotes (bacteria and archaea), although there are some exceptions, such as Mycoplasma, which require cholesterol for growth. Cholesterol also serves as a precursor for the biosynthesis of steroid hormones, bile acid, and vitamin D. Elevated levels of cholesterol in the blood, especially when bound to low-density lipoprotein (LDL, often referred to as "bad cholesterol"), may increase the risk of cardiovascular disease. François Poulletier de la Salle first identified cholesterol in solid form in gallstones in 1769. In 1815, chemist Michel Eugène Chevreul named the compound "cholesterine".
Sources: en.wikipedia.org
==== Administering the department ==== The permanent under-secretary at the Environment Department, Sir John Garlick, described Heseltine's arrival as a change from "a very conservative Labour secretary of state, Peter Shore, to a very radical Conservative Secretary of State". On his first day Heseltine took him out to lunch at the Connaught and drew up a list of what he wanted to accomplish in office (the list appears in Heseltine's book Where There's A Will, and was returned to him at the end of his time at the Environment). Only a quarter of Heseltine's agenda consisted of manifesto commitments and other political goals; the rest of it consisted of administrative and organisational changes. Peter Hennessy observed that Heseltine was more interested in the nuts and bolts of Whitehall reform than any minister since David Lloyd George. Heseltine was quite ruthless about moving civil servants with whom he was dissatisfied, but nonetheless staff thought he had mellowed somewhat since the early 1970s, and was more relaxed and fun to work with. His permanent secretaries Sir John Garlick and Sir George Moseley thought highly of him. He preferred to reach decisions through informal discussion rather than wading through paperwork. He instituted Peter Walker's custom of morning "prayer" meetings (ministers and PPSs with no civil servants present), now common in Whitehall but an innovation at the time. The department had a budget of £14 billion a year and employed 52,000 people. The Conservatives were pledged to cut 100,000 off the 730,000 strong civil service.
Tyrosine kinases recruited to a receptor following hormone binding are receptor-associated tyrosine kinases and are involved in a number of signaling cascades, in particular those involved in cytokine signaling (but also others, including growth hormone). One such receptor-associated tyrosine kinase is Janus kinase (JAK), many of whose effects are mediated by STAT proteins. (See JAK-STAT pathway.)
== Comparison with other purification methods == Biomolecules are often purified via solvent gradient batch chromatography. Here smooth linear solvent gradients are applied to carefully handle the separation between the desired component and hundreds of impurities. The desired product is usually intermediate between weakly and strongly absorbing impurities. A center cut is required to get the desired pure product. Often the preparative resins have a low efficiency due to strong axial dispersion and slow mass transfer. Then a purification in one chromatographic step is not possible. Countercurrent movement as known from the SMB process would be required. For large scale productions and for very valuable molecules countercurrent solid movement need to be applied to increase the separation efficiency, the yield and the productivity of the purification. The MCSGP process combines both techniques in one process, the countercurrent SMB principle and the solvent gradient batch technique. Discontinuous mode consists of equilibration, loading, washing, purification and regeneration steps. The discontinuous mode of operation allows exploiting the advantage of solvent gradients, but it implies high solvent consumptions and low productivities with respect to continuous countercurrent processes. An established process of this kind is the simulated moving bed technique (SMB) that requires the solvent-consuming steps of equilibration, washing, regeneration only once per operation and has a better resin utilization.
=== Sulfur insertion into unreactive C-H bonds === Sulfurtransferases are a small subset of radical SAM enzymes. Two well-known examples are BioB and LipA which are independently responsible for biotin synthesis and lipoic acid metabolism, respectively.
An RF value will always be in the range 0 to 1; if the substance moves, it can only move in the direction of the solvent flow, and cannot move faster than the solvent. For example, if particular substance in an unknown mixture travels 2.5 cm and the solvent front travels 5.0 cm, the retardation factor would be 0.50. One can choose a mobile phase with different characteristics (particularly polarity) in order to control how far the substance being investigated migrates. An RF value is characteristic for any given compound (provided that the same stationary and mobile phases are used). It can provide corroborative evidence as to the identity of a compound. If the identity of a compound is suspected but not yet proven, an authentic sample of the compound, or standard, is spotted and run on a TLC plate side by side (or on top of each other) with the compound in question. Note that this identity check must be performed on a single plate, because it is difficult to duplicate all the factors which influence RF exactly from experiment to experiment.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.